dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Perez-Fidalgo, J. A. |
dc.contributor.author | Cortés, A. |
dc.contributor.author | Guerra, Eva |
dc.contributor.author | García, Y. |
dc.contributor.author | Iglesias, M. |
dc.contributor.author | Bohn Sarmiento, U. |
dc.contributor.author | Oaknin Benzaquen, Ana Mazaltob |
dc.date.accessioned | 2022-03-23T12:18:26Z |
dc.date.available | 2022-03-23T12:18:26Z |
dc.date.issued | 2021-08 |
dc.identifier.citation | Perez-Fidalgo JA, Cortés A, Guerra E, García Y, Iglesias M, Bohn Sarmiento U, et al. Olaparib in combination with pegylated liposomal doxorubicin for platinum-resistant ovarian cancer regardless of BRCA status: a GEICO phase II trial (ROLANDO study). ESMO open. 2021 Aug;6(4):100212. |
dc.identifier.issn | 2059-7029 |
dc.identifier.uri | https://hdl.handle.net/11351/7255 |
dc.description | Inhibidor de PARP; Olaparib; Cáncer de ovario recurrente resistente al platino |
dc.language.iso | eng |
dc.publisher | Elsevier |
dc.relation.ispartofseries | ESMO Open;6(4) |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
dc.source | Scientia |
dc.subject | Quimioteràpia combinada |
dc.subject | Avaluació de resultats (Assistència sanitària) |
dc.subject | Ovaris - Càncer - Tractament |
dc.subject.mesh | Ovarian Neoplasms |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Antineoplastic Combined Chemotherapy Protocols |
dc.subject.mesh | /therapeutic use |
dc.title | Olaparib in combination with pegylated liposomal doxorubicin for platinum-resistant ovarian cancer regardless of BRCA status: a GEICO phase II trial (ROLANDO study) |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1016/j.esmoop.2021.100212 |
dc.subject.decs | neoplasias ováricas |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | protocolos de quimioterapia antineoplásica combinada |
dc.subject.decs | /uso terapéutico |
dc.relation.publishversion | https://doi.org/10.1016/j.esmoop.2021.100212 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Perez-Fidalgo JA] Department of Medical Oncology, Hospital Clínico Universitario de Valencia, Valencia, Spain. [Cortés A, Guerra E] Department of Medical Oncology, Hospital Universitario Ramón y Cajal, Madrid, Spain. [García Y] Department of Medical Oncology, Parc Taulí Hospital Universitari, Institut d'Investigació i Innovació Parc Taulí (I3PT), Universitat Autònoma de Barcelona, Sabadell, Spain. [Iglesias M] Department of Medical Oncology, Hospital Son Llatzer, Palma De Mallorca, Spain. [Bohn Sarmiento U] Department of Medical Oncology, Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas De Gran Canaria, Spain. [Oaknin A] Servei d’Oncologia Mèdica, Vall d'Hebron Hospital Universitari, Barcelona, Spain |
dc.identifier.pmid | 34329939 |
dc.identifier.wos | 000703610200048 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |